Clinical trial NCT06564155: Inturlekin L33 in Ankylosing Spondylities Patients and Its Relation to Subclinical Atherosclerosis
Official title: Inturlekin 33 in Ankylosing Spondylitis Patients and Its Relationship to Subclinical Atherosclerosis
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Ankylosing Spondylitis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-08-21
Enrollment: 45
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: * patient diagnosed as Ankylosing Spondylitis according to ASAS 2009
* Age (20-40)

Brief summary: detect level of Inturlekin 33 in ankylosing spondyilits patient

measure CIMT (carotid intima media thickness ) by carotid duplex to detect subclinical atherosclerosis in ankylosing spondyitis patients

detect the relation between IL33 and subclinical atherosclerosis in Ankylosinig Spondylitis patients

Detailed description: Ankylosing spondylitis (AS), a type of SpA, is an autoimmune disease that mainly involves, sacroiliac joints (SIJs) and their adjacent soft tissues, such as tendons and ligaments. The main clinical manifestations include back pain and progressive spinal rigidity as well as inflammation of the hips, shoulders, peripheral joints and fingers/toes. In addition, there are extra-articular manifestations.

Cardiovascular disease has become the first cause of death for patients with ankylosing spondylitis (AS).

Patients with ankylosing spondylitis (AS) have an increased cardiovascular morbidity and mortality . Accelerated atherosclerosis caused by a systemic inflammatory response has been reported to be an important risk factor for increased cardiovascular risk for autoimmune diseases.

Interleukin (IL)-33 is a cytokine belonging to the IL-1 family and was recently identified as a ligand for ST2, .the serum levels of IL-33/sST2 were remarkably higher in the patients with AS than the healthy groups .

Pervious studies confirm the importance of IL-33/ST2 axis in the process of atherosclerosis, and indicate its ambiguous function in immune response, whether as proinflammatory cytokine in advanced atherosclerotic lesions, or as profibrotic, in early lesions.

Previous study shows increased CIMT in AS patients without traditional cardiovascular risk factors compared to healthy controls.

Eligibility criteria: Inclusion Criteria:

* patient diagnosed as Ankylosing Spondylitis
* Age (20-40)

Exclusion Criteria:

* Patients with other rheumatic diseases/other SPA types

  * Participants with history of CVD event in past or present
  * Patient experiencing cardiovascular revascularization surgery or cerebrovascular disorder within past 6 months.
  * Patient with other risk factor for atherosclerosis.

Primary outcomes:
measure: detect level of IL33 in AS patients
timeFrame: 3 years
Secondary outcomes:
measure: detect the reation between IL33 and subclinical atherosclerosis in AS patients
timeFrame: 3 years
Other outcomes:
Locations:
Study officials:
References:
citation: Li GX, Wang S, Duan ZH, Zeng Z, Pan FM. Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis. Scand J Rheumatol. 2013;42(3):226-31. doi: 10.3109/03009742.2012.735700. Epub 2013 Feb 15.